Hormonal
Insufficient or mistimed sleep disrupts circadian gene expression rhythms in peripheral tissues (e.g., liver, blood), leading to metabolic and immune dysregulation, while the central pacemaker (SCN) remains largely unaffected.
Prioritize consistent sleep duration and timing. Disrupting your sleep schedule (e.g., shift work, late sleeping) doesn't just make you tired; it fundamentally alters how your body's genes regulate metabolism and immunity. Protecting your circadian rhythm by sleeping at appropriate times is critical for preventing metabolic syndrome and other long-term health issues.
In mice, sleep restriction leads to an ~80% reduction in circadian transcripts in the brain and profound disruption of the liver transcriptome. In humans, sleep restriction leads to a 1.9% reduction in circadian transcripts in whole blood, and when sleep is displaced to the daytime, 97% of rhythmic genes become arrhythmic... These changes in mice and humans include a significant reduction in the circadian regulation of transcription and translation and core clock genes in the periphery, while at the same time rhythms within the suprachiasmatic nucleus are not disrupted.
Why this rating
The paper reviews multiple animal and human transcriptomic studies, providing strong mechanistic evidence, though it is a review rather than a single clinical trial.
Source
How sleep and wakefulness influence circadian rhythmicity: effects of insufficient and mistimed sleep on the animal and human transcriptome
Simon Archer et al. · Journal of Sleep Research · 2015
DOI 10.1111/jsr.12307
More from this paper
- Mistimed sleep (sleeping during the day) causes a massive arrhythmicity in peripheral gene expression, with 97% of rhythmic genes becoming arrhythmic in humans.Good
- Sleep disruption is associated with an increased risk of metabolic syndrome, type-2 diabetes, and certain cancers through mechanisms involving altered gene expression, hormone levels, and immune response.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →